The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy

Drugs

Volumn 61, Issue 1, 2001, Pages 19-26

  Moyle, G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; DELAVIRDINE; DMP 006; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TERFENADINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION;

EID: 0035138694     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161010-00003     Document Type: Review

References (18)

1. 1998 revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals
2. Antiretroviral therapy for HIV infection in 1998
3. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
5. Assessment of risk versus benefit for therapeutic intervention with HIV Protease inhibitors
6. The Atlantic study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing anti-retroviral strategies versus a standard PI-containing regimen: Final 48 week data
7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
8. Second placebo-controlled study in naive individuals confirms the role of delavirdine in highly active antiretroviral, protease-sparing treatment
9. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine in HIV-infected patients: The INCAS trial
10. A phase II, double blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, Sustiva, DMP 266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) at 36 weeks (DMP 266-005)
11. ACTG 364: Virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFZ) in combination with new nucleoside analogs in nucleoside experienced subjects
12. A randomized, open, multicenter trial comparing combivir plus nelfinavir or nevirapine in HIV-infected naive patients (the Combine Study)
13. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1 infected persons with prior nucleoside analogue and protease inhibitor use
14. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse transcriptase inhibitor, DMP 266
15. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
16. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection
17. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1 infected persons on initial therapy
18. Evaluation of lymph node burden in HIV-infected individuals receiving an efavirenz-based protease-inhibitor sparing HAART regimen